Atossa Therapeutics (ATOS) Research & Development (2012 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Research & Development of $4.8 million for Q1 2026, up 14.96% year-over-year from $4.2 million in Q1 2025, and down 22.37% quarter-over-quarter from $6.2 million in Q4 2025.
Atossa Therapeutics (ATOS) Research & Development (2012 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Research & Development for 15 consecutive years, with $4.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 14.96% year-over-year to $4.8 million; the TTM figure through Mar 2026 stood at $21.8 million (up 50.13% YoY), while the FY2025 annual figure was $21.2 million, up 50.07% from the prior year.
- Research & Development fell to $4.8 million in Q1 2026 per ATOS's latest filing, from $6.2 million in the prior quarter.
- Across five years, Research & Development topped out at $6.2 million in Q4 2025 and bottomed at $1.5 million in Q1 2022.
- Historically, Research & Development has averaged $4.3 million across 5 years, with a median of $4.2 million in 2025.
- Annual changes were most pronounced in 2022 — Research & Development jumped 172.91% — and 2024, when it sank 39.81%.
- Atossa Therapeutics' Research & Development stood at $5.0 million in 2022, then gained by 13.4% to $5.7 million in 2023, then tumbled by 39.81% to $3.4 million in 2024, then soared by 80.9% to $6.2 million in 2025, then retreated by 22.37% to $4.8 million in 2026.
- Business Quant data shows ATOS's Research & Development at $4.8 million in Q1 2026, $6.2 million in Q4 2025, and $5.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Atossa Therapeutics | 23.12 Mn | 23.12 Mn | - | 4.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.90 Mn |
| Mar 31, 2026 | 4.78 Mn |
| Dec 31, 2025 | 6.16 Mn |
| Sep 30, 2025 | 5.37 Mn |
| Jun 30, 2025 | 5.50 Mn |
| Mar 31, 2025 | 4.16 Mn |
| Dec 31, 2024 | 3.40 Mn |
| Sep 30, 2024 | 3.41 Mn |
| Jun 30, 2024 | 3.55 Mn |
| Mar 31, 2024 | 3.75 Mn |
| Dec 31, 2023 | 5.65 Mn |
| Sep 30, 2023 | 4.47 Mn |
| Jun 30, 2023 | 3.71 Mn |
| Mar 31, 2023 | 3.51 Mn |
| Dec 31, 2022 | 4.99 Mn |
| Sep 30, 2022 | 5.16 Mn |
| Jun 30, 2022 | 3.43 Mn |
| Mar 31, 2022 | 1.50 Mn |
| Dec 31, 2021 | 1.83 Mn |
| Sep 30, 2021 | 2.21 Mn |